| 2020 |
Cornelissen D, Boonen A, Bours S, Evers S, Dirksen C, Hiligsmann M. Understanding patients’ preferences for osteoporosis treatment: the impact of patients’ characteristics on subgroups and latent classes. Osteoporos Int. January 2020;31(1):85-96. |
1 |
1 |
| 2020 |
de Bot RTAL, Veldman HD, Witlox AM, van Rhijn LW, Hiligsmann M. Hip protectors are cost-effective in the prevention of hip fractures in patients with high fracture risk. Osteoporos Int. July 2020;31(7):1217-1229. |
0 |
0 |
| 2020 |
Cornelissen D, Kunder Sd, Si L, Reginster J-Y, Evers S, Boonen A, Hiligsmann M; European Society for Clinical and Economic Aspect of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Interventions to improve adherence to anti-osteoporosis medications: an updated systematic review. Osteoporos Int. September 2020;31(9):1645-1669. |
1 |
1 |
| 2021 |
Chandran M, Ganesan G, Tan KB, Reginster J-Y, Hiligsmann M. Cost-effectiveness of FRAX®-based intervention thresholds for management of osteoporosis in Singaporean women. Osteoporos Int. January 2021;32(1):133-144. |
0 |
0 |
| 2021 |
Hiligsmann M, Maggi S, Veronese N, Sartori L, Reginster J-Y. Cost-effectiveness of buffered soluble alendronate 70 mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in iItaly. Osteoporos Int. March 2021;32(3):595-606. |
0 |
0 |
| 2021 |
Chandran M, Ganesan G, Tan KB, Reginster J-Y, Hiligsmann M. Using health-economic evidence to support policy-level decision-making in Singapore: sensitivity analysis that provides further confidence in fracture probability-based cost-effective intervention thresholds. Osteoporos Int. April 2021;32(4):787-789. |
0 |
0 |